Sanofi: finalises Praluent restructuring agreement

(CercleFinance.com) - Sanofi announces that it has finalised planned restructuring relating to Praluent (alirocumab) with Regeneron, which "Simplifies the antibody collaboration between the companies, increases efficiency, and streamlines operations for Praluent".
 

From 1 April 2020, Sanofi will have full responsibility for Praulent outside the United States, while Regeneron will have full responsibility within the United States. Both health groups have signed agreements to meet short-term manufacturing requirements.

Sanofi is continuing to work on the evaluation of Kevzara-related restructuring, taking into account recent US and global clinical programs evaluating Kevzara in hospitalised patients with severe forms of Covid-19.


Copyright (c) 2020 CercleFinance.com. All rights reserved.